α1b-adrenergic receptor antagonists
AssigneeToray Industries, Inc.
InventorsRyoji Hayashi, Eiji Ohmori, Masafumi Isogaya, Mitsuhiro Moriwaki, Hiroki Kumagai
Life of this patent
Estimating the term…
Loading patent…
AssigneeToray Industries, Inc.
InventorsRyoji Hayashi, Eiji Ohmori, Masafumi Isogaya, Mitsuhiro Moriwaki, Hiroki Kumagai
Estimating the term…
There are provided compounds represented by the general formula (I): [wherein Ar is indole etc., R1 is hydrogen etc., B is bond, or B—N—R1 forms a ring structure and is piperidine etc., n is 0, 1, etc., A is trimethylene, butylene, etc., Q is piperidine, isoindoline, etc.], or pharmacologically acceptable acid addition salts thereof, and α1B adrenoceptor antagonists composed of these substances. The invented compounds are antagonists having high affinity for α1B adrenoceptor and are useful as pharmaceutical agents for use in prophylaxis/therapy of diseases (e.g., hypertension) in which α1B adrenoceptor is involved or as pharmacological tools for elucidation of physiological activities mediated by α1B adrenoceptor.
A method of treating diseases selected from the group consisting of ocular tension, carcinoma, sarcoma and tumentia comprising administering to a patient a therapeutically effective amount of an α1B adrenoceptor antagonist compound represented by the formula (I) or a pharmacologically acceptable acid addition salt thereof:
A method for treating circulatory disease comprising administering to a patient a therapeutically effective amount of an aiB adrenoceptor compound represented by the formula (I) or a pharmacologically acceptable acid addition salt thereof:
A method for treating hypertension comprising administering to a patient a therapeutically effective amount of an α1 B adrenoceptor compound represented by the formula (I) or a pharmacologically acceptable acid addition salt thereof:
A compound represented by the formula (III), or a pharmacologically accet table acid addition salt thereof:
Dependencies are inferred from the claim text.